237 results Diversiteit Op 1 januari 2022 is de Wet ingroeiquotum en streefcijfers ("Diversiteitswet") in werking getreden. ACM is verplicht om het besluit waarin zij afziet tot oplegging van een boete te publiceren De Instellingswet Autoriteit Consument en Markt verplicht de ACM om een besluit waarbij een ernstige overtreding (zoals overtreding van het kartelverbod) is geconstateerd, maar waarbij is afgezien van het opleggen van een boete toch openbaar te maken. Over temperaturen ten tijde van corona De Autoriteit Persoonsgegevens (AP) verheldert haar standpunt met betrekking tot temperatuurmetingen bij werknemers. Als geen persoonsgegevens worden verwerkt, is de AVG niet van toepassing en kan de AP niet handhaven. Stibbe advises Aedifica Stibbe has advised Aedifica on the acquisition and lease of a care residence to be constructed in Lelystad and the acquisition and lease of a recently completed care residence in Zwolle. Breaking news from the CJEU: no SPCs for new therapeutic applications On 9 July 2020, the Grand Chamber of the CJEU ruled on the interpretation of Article 3(d) of Regulation 469/2009 concerning the supplementary protection certificate (CCP) for medicinal products. Stand van zaken Wet zorgplicht kinderarbeid De Wet Zorgplicht Kinderarbeid is op 13 november 2019 in het Staatsblad gepubliceerd. Het doel van de wet is om te voorkomen dat er goederen en diensten die tot stand zijn gekomen met behulp van kinderarbeid in Nederland verkocht of geleverd worden. Stibbe advises KLM and Martinair - CFI and EWD Representing KLM and its subsidiary Martinair in antitrust damage litigation in the Amsterdam District Court. Stibbe advises AkzoNobel and Eka Stibbe advises Vodafone Advising Vodafone in an investigation by the ACM (formerly known as the NMa) into the Dutch telecom sector leading to a commitment decision. Stibbe advises an international consumer products company Stibbe advises MBO Raad Stibbe advises major European retailer Stibbe represented a major European retailer on the largest cartel investigation ever in Belgium regarding DPH products (drugstore, perfume, and hygienic products). Stibbe advises a foreign bank and its management Stibbe advises the chairman of a board Stibbe advises leading pharmaceutical company Stibbe assisted a leading pharmaceutical company in identifying the most cost-effective way to obtain in Belgium an improved pricing and reimbursement for new fixed-dose combination products composed of off-patent ingredients. Stibbe advises warehouse operator in the port of Antwerp Stibbe assisted a warehousing company in the port of Antwerp in the competition law investigation, provisional measures, and appeal proceedings regarding alleged abuse of a dominant position for the load out of certified LIFFE coffee in the port. Stibbe advises Canon Advising Canon in connection with their dispute with the State of the Netherlands on the procurement of framework contracts. Case won up to and including the Supreme Court. Stibbe advises Mylan Stibbe advises global pharmaceutical company Mylan on the merger control aspects of its USD 7.2 billion acquisition of Swedish drugmaker Meda. Pagination Previous page Page 9 Current page 10 Page 11 Page 12 Next page
Diversiteit Op 1 januari 2022 is de Wet ingroeiquotum en streefcijfers ("Diversiteitswet") in werking getreden.
ACM is verplicht om het besluit waarin zij afziet tot oplegging van een boete te publiceren De Instellingswet Autoriteit Consument en Markt verplicht de ACM om een besluit waarbij een ernstige overtreding (zoals overtreding van het kartelverbod) is geconstateerd, maar waarbij is afgezien van het opleggen van een boete toch openbaar te maken.
Over temperaturen ten tijde van corona De Autoriteit Persoonsgegevens (AP) verheldert haar standpunt met betrekking tot temperatuurmetingen bij werknemers. Als geen persoonsgegevens worden verwerkt, is de AVG niet van toepassing en kan de AP niet handhaven.
Stibbe advises Aedifica Stibbe has advised Aedifica on the acquisition and lease of a care residence to be constructed in Lelystad and the acquisition and lease of a recently completed care residence in Zwolle.
Breaking news from the CJEU: no SPCs for new therapeutic applications On 9 July 2020, the Grand Chamber of the CJEU ruled on the interpretation of Article 3(d) of Regulation 469/2009 concerning the supplementary protection certificate (CCP) for medicinal products.
Stand van zaken Wet zorgplicht kinderarbeid De Wet Zorgplicht Kinderarbeid is op 13 november 2019 in het Staatsblad gepubliceerd. Het doel van de wet is om te voorkomen dat er goederen en diensten die tot stand zijn gekomen met behulp van kinderarbeid in Nederland verkocht of geleverd worden.
Stibbe advises KLM and Martinair - CFI and EWD Representing KLM and its subsidiary Martinair in antitrust damage litigation in the Amsterdam District Court.
Stibbe advises Vodafone Advising Vodafone in an investigation by the ACM (formerly known as the NMa) into the Dutch telecom sector leading to a commitment decision.
Stibbe advises major European retailer Stibbe represented a major European retailer on the largest cartel investigation ever in Belgium regarding DPH products (drugstore, perfume, and hygienic products).
Stibbe advises leading pharmaceutical company Stibbe assisted a leading pharmaceutical company in identifying the most cost-effective way to obtain in Belgium an improved pricing and reimbursement for new fixed-dose combination products composed of off-patent ingredients.
Stibbe advises warehouse operator in the port of Antwerp Stibbe assisted a warehousing company in the port of Antwerp in the competition law investigation, provisional measures, and appeal proceedings regarding alleged abuse of a dominant position for the load out of certified LIFFE coffee in the port.
Stibbe advises Canon Advising Canon in connection with their dispute with the State of the Netherlands on the procurement of framework contracts. Case won up to and including the Supreme Court.
Stibbe advises Mylan Stibbe advises global pharmaceutical company Mylan on the merger control aspects of its USD 7.2 billion acquisition of Swedish drugmaker Meda.